Astria Therapeutics, Inc. (ATXS)

Market Cap	538.05M
Revenue (ttm)	n/a
Net Income (ttm)	-72.89M
Shares Out	54.90M
EPS (ttm)	-2.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,526,213
Open	9.86
Previous Close	9.75
Day's Range	9.53 - 10.01
52-Week Range	4.26 - 16.90
Beta	0.71
Analysts	Strong Buy
Price Target	21.75 (+121.94%)
Earnings Date	May 9, 2024

About ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder ass...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: ATXS

Analyst Forecast

According to 4 analysts, the average rating for ATXS stock is "Strong Buy." The 12-month stock price forecast is $21.75, which is an increase of 121.94% from the latest price.

Price Target

$21.75

(121.94% upside)

Analyst Consensus: Strong Buy